Understanding genetic factors in alcoholic liver disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the prevalence of alcoholic hepatitis among patients with jaundice and evaluate their outcomes based on disease severity. It will involve collecting data on liver dysfunction and survival rates, while also creating a biobank for genetic samples to explore the disease's inflammatory and regenerative profiles. Additionally, the study will investigate the effectiveness of non-invasive diagnostic criteria for alcoholic hepatitis. The research will be conducted across multiple centers to gather a diverse cohort of patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

For SAH group:

* Alcohol consumption :

  * On average\> 40 g / day for women and 50 g / day for men
  * Duration:\> 5 years
* Recent jaundice episode (less than 3 months)
* Bilirubin\> 50 mg / l (85μmol / l)

For NSAH group:

\- Alcohol consumption :

* On average\> 40 g / day for women and 50 g / day for men
* Duration:\> 5 years

For cirrhosis (control) group:

* Alcohol consumption :

  * On average\> 40 g / day for women and 50 g / day for men
  * Duration:\> 5 years
* Unambiguous presence of cirrhosis criteria, including:

  * clinical signs (ascites, stellar angiomas ...) and / or
  * radiological signs (scanner or MRI: signs of hepatic dysmorphism and / or portal hypertension) and / or
  * biological signs (increased INR, thrombocytopenia) and / or
  * endoscopic signs (oesophageal / gastric varices)

Exclusion Criteria:

For NAH and NSAH groups:

* Presence of another hepatic pathology: evidenced by blood biology, imaging or histology (viral or autoimmune hepatitis, hemochromatosis, Wilson's disease)
* Presence of hepatocellular carcinoma
* HIV infection

For cirrhosis (control) group:

* History established / suggestive of HAA (Clinical, biological and / or histological criteria) in particular absence of jaundice episode
* Presence of another hepatic pathology: evidenced by blood biology, imaging or histology (viral or autoimmune hepatitis, hemochromatosis, Wilson's disease)
* Presence of hepatocellular carcinoma
* HIV infection

Where it's running

• Chr Angers
  Angers, France Recruiting
• Chru Besancon
  Besançon, France Recruiting
• Hôpital Jean Verdier, AH-HP
  Bondy, France Recruiting
• Centre Hospitalier Universitaire
  Caen, France Recruiting
• Hopital Nord - Chu38 - La Tronche
  La Tronche, France Recruiting
• Hôpital Claude Huriez, CHU
  Lille, France Recruiting

Study contacts

• Principal investigator: Alexandre Louvet, MD,PhD — University Hospital, Lille
• Study coordinator: Alexandre Louvet, MD,PhD
• Email: alexandre.louvet@chru-lille.fr
• Phone: 03 20 44 55 97

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Optimizing recovery in patients with alcohol-related liver cirrhosis

  This study is testing if motivational interviews along with regular care can help people with alcohol-related liver cirrhosis improve their liver function and slow down the disease.

  Recruiting Copenhagen University Hospital, Hvidovre · Hvidovre, Capital Region · NCT06866496

• Exploring the role of gut bacteria in alcoholic hepatitis

  This study is trying to see how gut bacteria affect liver damage in people with severe alcoholic hepatitis to find new ways to help them feel better.

  Recruiting Hospices Civils de Lyon · Lyon · NCT06307964

• Cohort study on the impact of gut microbiome in alcoholic liver disease

  This study is trying to see how the gut bacteria of heavy drinkers affects the development and worsening of alcoholic liver disease.

  Recruiting Assistance Publique - Hôpitaux de Paris · Clamart, Île-de-France Region · NCT05895890

• Evaluating liver disease screening for individuals with alcohol use disorder

  This study tests if screening for liver disease with a special measurement helps people in alcohol treatment stay sober or drink less over six months.

  Recruiting at 2 sites Zealand University Hospital · Køge and 1 other locations · NCT05855031

• HMB supplementation for patients with alcoholic liver disease and COVID-19

  This study is testing if HMB supplements can help people with alcoholic liver disease who also have COVID-19 feel better and recover more effectively.

  Recruiting The Cleveland Clinic · Cleveland, Ohio · NCT04858412

• Evaluating Cellgram-LC for Alcoholic Cirrhosis Treatment

  This study is testing whether a new treatment using stem cells can help people with alcoholic cirrhosis feel better and improve their liver health.

  Recruiting at 12 sites Phase 3 Pharmicell Co., Ltd. · Ansan and 14 other locations · NCT04689152

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.